Sign in

What researchers published on Myelodysplastic syndromes

7,682 papers, newest first.

Showing 160 of 7,682

  • Fever of Unknown Origin in Myelodysplastic Syndrome: Clinical and Laboratory Features of a Chinese Cohort.Journal of clinical medicine
  • Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR.Blood
  • Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS.Blood
  • Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.Haematologica
  • Exploring neuropsychological alterations in VEXAS syndrome.Clinical and experimental medicine
  • Case reportMyelodysplastic Syndrome With Isolated del(5q) Coexisting With Cold Agglutinin Disease Presenting as Unexplained Hyperbilirubinemia.Cureus
  • Development and validation of a baseline interpretable prognostic model for mortality risk stratification in myelodysplastic syndrome patients receiving hypomethylating agent therapy.Current problems in cancer
  • MicroRNA dysregulation in mesenchymal stromal cells in myelodysplastic syndromes and its modulation by azacitidine and bortezomib.Leukemia & lymphoma
  • ReviewSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia
  • Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells.Leukemia
  • Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes.Blood neoplasia
  • PreprintPersistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms.bioRxiv : the preprint server for biology
  • Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non-Erythroid Blood Counts.Hematological oncology
  • Impact of Venetoclax Bridging on Haematopoietic Stem Cell Transplantation Outcomes in Advanced Myelodysplastic Neoplasms.Transplantation and cellular therapy
  • NUDT21 knockdown modulates alternative polyadenylation and promotes leukemic transformation in myelodysplastic syndromes.Neoplasma
  • Molecular and clinical profiling of SF3B1, U2AF1, and SRSF2 mutations in Iranian patients with myelodysplastic neoplasms.Molecular biology reports
  • Frontline isocitrate dehydrogenase inhibitor therapy in isocitrate dehydrogenase-mutated myelodysplastic neoplasms.Haematologica
  • Prevalence and prognostic implications of systemic autoinflammatory and autoimmune diseases in myelodysplastic neoplasms: a retrospective Belgian cohort study.Clinical and experimental medicine
  • GATA2 Deficiency Presenting With a WHIM-Like Phenotype and Subsequent Development of Monosomy 7-Associated Myelodysplastic Syndrome in an Adolescent Female: A Case Report.Clinical case reports
  • Review[Hematological features and advancement in the diagnosis of VEXAS syndrome].Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • Willingness to Pay for Temporary Transfusion Independence in Lower-Risk Myelodysplastic Syndromes: Evidence from a Cross-Sectional Study in China.Patient preference and adherence
  • Complement deposition in the bone marrow of patients with myelodysplastic neoplasms.Signal transduction and targeted therapy
  • Can we better evaluate responses in higher-risk myelodysplastic syndromes?Haematologica
  • Infectious burden and cellular immune impairment in higher-risk myelodysplastic syndromes with biallelic TP53 alterations.Frontiers in cellular and infection microbiology
  • Review[Advances in the management of myelodysplastic neoplasms].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • Case reportPearls & Oy-sters: Beyond the Bone Marrow-VEXAS Syndrome Presenting as Subacute Encephalomyelitis.Neurology
  • A Novel Insight Into Luspatercept: Therapeutic Implications in Myelodysplastic Syndrome Patients With Elevated Pulmonary Artery Systolic Pressure.Pulmonary circulation
  • IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC).Transplantation and cellular therapy
  • Comparison of Fludarabine/Treosulfan Conditioning with Melphalan-Based Sequential Conditioning in Patients with MDS and Increased Blasts Undergoing Upfront Transplantation.Cancers
  • ReviewDiagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy.Genes
  • Correction: Balaian et al. Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia. Metabolites 2026, 16, 648.Metabolites
  • Inflammasome activation promotes the progression of myelodysplastic syndrome.Experimental hematology
  • Post-transplant monitoring of NGS-based measurable residual disease and donor chimerism as a prognostic tool in older patients with AML/MDS.Blood research
  • ReviewClinical applications of CD34+ progenitor cell immunophenotyping in myelodysplastic neoplasms-The CytHem SMD French network experience.Cytometry. Part B, Clinical cytometry
  • PreprintMulti-hit STAG2 mutations define a high-risk subset of MDS and reveal convergent evolutionary targeting of cohesin.bioRxiv : the preprint server for biology
  • From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy.Seminars in hematology
  • Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia.JCI insight
  • A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome.Clinical immunology (Orlando, Fla.)
  • A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine.Blood neoplasia
  • Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.Blood neoplasia
  • Case reportA rare case of acute basophilic leukemia transformed from high risk myelodysplastic syndrome.Annals of hematology
  • ReviewPersonalized allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes: Integrating molecular risk, donor selection, and post-transplant strategies.Cell transplantation
  • Venetoclax-based combinations in high-risk myelodysplastic syndromes: highlights from ASH 2025 & EHA 2026.Experimental hematology & oncology
  • Review[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].Bulletin du cancer
  • Association between chronic kidney disease and the risk of myelodysplastic syndromes: A large claims database study in Japan.British journal of haematology
  • Financial burden to patients and informal carers of myelodysplastic syndromes in England: a modelled analysis stratified by transfusion dependence.Leukemia research
  • Synchronous myelodysplastic syndrome and multiple myeloma: a DDX41-associated double-hit across two lineages.Archives of medical science : AMS
  • Perspectives on FDA Guidance for Myelodysplastic Syndromes.Blood advances
  • A Stem Cell-based Flow Cytometry Assay to Predict Post-transplantation Relapse in Patients With Myelodysplastic Syndromes With Excess Blasts: A Prospective Study.Transplantation and cellular therapy
  • ReviewOncostatin M deficiency: A newly recognized inherited bone marrow failure syndrome with potential predisposition to myeloid malignancy.Hematology/oncology and stem cell therapy
  • Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.Blood
  • Case reportAortic-renal aneurysm in a patient with VEXAS syndrome treated with Tocilizumab.ARP rheumatology
  • Case reportDe novo development of JAK2V617F-positive polycythemia vera following allogeneic hematopoietic stem cell transplantation: a report of two rare cases.Upsala journal of medical sciences
  • Case reportClinical Images: Collapsing auricles and airways in relapsing polychondritis with myelodysplastic syndrome.ACR open rheumatology
  • Recurrent Invasive Staphylococcus aureus Infections in a Non-Neutropenic Hemodialysis Patient With Myelodysplastic Syndrome: A Case Report.Case reports in nephrology
  • Case report[Gecacitinib as a bridging treatment to allogeneic hematopoietic stem cell transplantation for high-risk myelodysplastic syndrome with Behçet's syndrome: a case report].Zhonghua nei ke za zhi
  • A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19.Leukemia research reports
  • Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based Study.ClinicoEconomics and outcomes research : CEOR
  • [Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML.Genes, chromosomes & cancer
  • Case reportMyelodysplastic Syndromes-Transformed Acute Myeloid Leukemia With Concurrent DEK::CAN Fusion Gene Positivity and WT1 Overexpression: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.)
  • Case reportSF3B1-mutated MDS coexisting with β-thalassemia trait: A case report and literature review focused on diagnostic distinction from acquired β-thalassemia.Medicine
  • Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study.Leukemia
  • Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome.Clinical laboratory
  • Long-read sequencing and the boundary conditions for multi-hit reassurance in TP53-mutated myelodysplastic syndrome. Comment on: "Long-read sequencing resolves TP53 allelic status in myeloid neoplasms".Haematologica
  • Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.Haematologica
  • ReviewMyelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity.Expert review of anticancer therapy
  • ReviewUBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications.Frontiers in immunology
  • Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.Blood
  • Correction: spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.Leukemia
  • Preemptive and Therapeutic Donor Lymphocyte Infusion for Acute Leukemia or Myelodysplastic Syndromes: A Real-World Single-Center Study.Transplantation and cellular therapy
  • Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.Acta haematologica
  • ReviewInterest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients.Blood research
  • Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.Leukemia
  • Auto-immune diseases associated with myelodysplastic syndrome and chronic myelomonocytic leukemia do not impact allogenic transplantation outcomes.Bone marrow transplantation
  • CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.Blood neoplasia
  • Case reportEarly-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation.Journal of hematopathology
  • Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation.Molecular and cellular pediatrics
  • Trial resultPhase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.Cancer
  • Increased glioblastoma risk in patients with myeloproliferative neoplasms and myelodysplastic syndromes.Clinical and experimental medicine
  • Decitabine induces cell differentiation and growth inhibition accompanied by upregulation of microRNA-143 and MS4A3 in the myelodysplastic syndromes-derived leukemic cell line MDS-L.Oncology letters
  • Single-cell transcriptomic characterization of a human MDS hematopoietic dataset and in vitro validation of apoptosis-related venetoclax resistance in human MDS-L cells.Frontiers in cell and developmental biology
  • NUDT21 Promotes Myelodysplastic Syndrome Progression by Regulating SRSF2 Expression via Alternative Polyadenylation.Hematological oncology
  • Mitochondrial genetic variation as a novel predictor of graft-versus-host disease after stem-cell transplantation in myelodysplastic neoplasms.Journal of hematology & oncology
  • PreprintSomatic DDX41 mutations confer neomorphic splicing activity in the pathogenesis of myelodysplastic neoplasms.bioRxiv : the preprint server for biology
  • Functional Classification of Monoallelic TP53 Mutations Refines Prognostic Stratification in Myelodysplastic Neoplasms.Blood
  • Elucidating Mechanisms Underlying Fibrocyte-Mediated Myelofibrosis Induction in Myelodysplastic Syndromes.Frontiers in bioscience (Landmark edition)
  • Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party.Bone marrow transplantation
  • DNA methylation status at diagnosis in MDS predicts response to azacitidine.The Journal of clinical investigation
  • [High-Risk Factors for Transformation to Acute Myeloid Leukemia in Patients with Higher-Risk Myelodysplastic Syndromes Undergoing Hypomethylating Agents].Zhongguo shi yan xue ye xue za zhi
  • [Efficacy and Safety of Venetoclax Combined with Azacitidine versus Azacitidine Monotherapy in the Treatment of Higher-Risk Myelodysplastic Syndromes].Zhongguo shi yan xue ye xue za zhi
  • ReviewThe Runx1-Gata2 axis: epigenetic architecture of lineage fate.Molecular biology reports
  • ReviewELN vs. IPSS-M in MDS/AML: Which Prognostic System Should Guide Clinical Decision-Making?Cancers
  • Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy.BMC cancer
  • Age over sibling: Younger unrelated donors provide superior outcomes compared to sibling donors in fully matched HCT in older AML/MDS patients.Leukemia research
  • Systematic reviewATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review.Medical oncology (Northwood, London, England)
  • Targeting TGFBR1 with the Investigational Inhibitor TP-6379 Improves Hematopoiesis in Low-Risk MDS Ex Vivo.Cells
  • Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia.Metabolites
  • Reversible Eltrombopag-Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1-Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report.EJHaem
  • Quality and reliability of myelodysplastic syndromes-related health information on Chinese short-video platforms: a multi-platform cross-sectional analysis.Frontiers in digital health
  • Grip strength is associated with overall survival in myelodysplastic syndrome.Blood advances
  • ReviewLenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms.Current oncology (Toronto, Ont.)
  • Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.Haematologica
  • A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS Progression.Blood advances
  • Case reportLung-Predominant Hyperinflammatory Syndrome in Therapy-Related Myelodysplastic Syndrome Responsive to Interleukin-1 Blockade.Hematology reports
  • A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma.Internal medicine (Tokyo, Japan)
  • Long-term Results of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Real-life Data of 15- and 20-year Survivals from a Single Center.Stem cell reviews and reports
  • Case reportCase Report: Central nervous system infiltration after allogeneic hematopoietic stem cell transplantation in high-risk myelodysplastic neoplasms.Frontiers in oncology
  • ReviewStrategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology
  • ReviewT lymphocytes and natural killer cells in myelodysplastic syndromes: function, dysfunction, and therapeutic potential.Frontiers in immunology
  • Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.Cancer
  • Case reportDiagnostic and Therapeutic Challenge: VEXAS Syndrome with Multisystem Inflammation and Myelodysplasia: A Case Report.Mediterranean journal of rheumatology
  • Case reportCo-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.Frontiers in medicine
  • Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.Communications medicine
  • Real-World Outcomes of Hypomethylating Agents for Higher-Risk Myelodysplastic Syndromes: Report From the Nationwide Multicenter Thai MDS Study.Advances in hematology
  • Case reportAcute Fulminant Systemic Granulocytic Vasculitis Involving Arteries and Veins in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: An Autopsy Case Report.Pathology international
  • Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.Annals of hematology
  • ReviewSelective Inhibition of DNA Polymerase Proofreading: A Metabolic-Fidelity Mechanism Explains Agent Orange-Associated Myelodysplasia.Cancers
  • ReviewClinical management of clonal hematopoiesis.Cancer
  • ReviewAge-Stratified Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes: A Comprehensive Review.Hematological oncology
  • ReviewAML, Myelodysplasia-Related: Beyond Classification-Toward Precision Decision-Making.Mediterranean journal of hematology and infectious diseases
  • Vexas Syndrome: A Multisystem Challenge with Sweet Syndrome and Myelodysplastic Syndrome.European journal of case reports in internal medicine
  • Superior outcomes with offspring B-leader-matched haploidentical versus older matched sibling donors in AL/MDS patients aged ≥40 years.Frontiers in immunology
  • Case reportDiffuse large B‑cell lymphoma followed by myelodysplastic syndrome with TP53 mutation: a case report and literature review.Frontiers in oncology
  • Elevated expression of heme metabolism genes as a favorable biomarker in SF3B1-mutated myelodysplastic neoplasms.Leukemia & lymphoma
  • Optimizing cord blood unit selection to improve survival after single-unit unrelated cord blood transplantation for adult myelodysplastic syndrome.British journal of haematology
  • Lupus-Like Chilblains in a Patient With Myelodysplastic Syndrome.Journal of cutaneous medicine and surgery
  • Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth.Frontiers in medicine
  • Review[Germline DDX41 mutations and myelodysplastic neoplasms].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Coagulation activation is associated with genomic-instability-related features in TP53-mutated AML and MDS: routine laboratory patterns beyond classical disseminated intravascular coagulation.Frontiers in cell and developmental biology
  • ReviewRecent advances in cell therapy for AML/MDS.International journal of hematology
  • Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.Leukemia
  • Case reportALK-fusion-positive non-small cell lung cancer concomitant with 5q deletion myelodysplastic syndrome: a case report.Frontiers in oncology
  • Integrative bioinformatic analysis delineates a mitochondrial-hematopoietic gene signature for diagnosis and immune characterization in myelodysplastic syndromes.Hematology (Amsterdam, Netherlands)
  • Corrigendum to "Qinghuang powder ameliorates cellular senescence and energy metabolism abnormalities in bone marrow mesenchymal stem cells of myelodysplastic syndromes" [J. Ethnopharmacol. 373 (2026) 122323].Journal of ethnopharmacology
  • Case reportClinical and molecular spectrum of VEXAS with multiple UBA1 variants: case study and literature review.American journal of clinical pathology
  • Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.Haematologica
  • ReviewInflammatory Network Architecture Across Bone Marrow Failure: An Immune-Genetic Continuum.Frontiers in bioscience (Landmark edition)
  • Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.Haematologica
  • ReviewSperm-associated antigen 6 (SPAG6): roles in human cancer and other diseases.Sheng li xue bao : [Acta physiologica Sinica]
  • Myelodysplastic neoplasms are inhibited by Brefeldin A through endoplasmic reticulum stress and autophagy.Sheng li xue bao : [Acta physiologica Sinica]
  • Infection risk in myelodysplastic syndromes is dynamic and immune driven.Blood advances
  • Review[Aberrant mitochondrial dynamics in myeloid neoplasms].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • [Comparison of clinical characteristics and cytogenetic abnormalities between myelodysplastic syndromes in Nagasaki atomic bomb survivors and therapy-related myelodysplastic syndromes].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • Review[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • ReviewRibosomal proteins, miRNAs, and extracellular vesicles in myelodysplastic syndromes: molecular regulation and biomarker potential.Frontiers in oncology
  • Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis.BMJ open
  • Sustained Erythroid Response to Eltrombopag in Low-Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report.Case reports in hematology
  • ReviewFunctional Characterization of Myelodysplastic Syndrome by Multiparameter Flow Cytometry: The Clinical Synergy Between Ki-67 and Bcl-2 and Their Potential Role in Diagnostics and Personalized Therapy.Cancers
  • A case of chronic myeloid leukaemia complicated by SF3B1-mutant myelodysplastic syndrome.British journal of haematology
  • Case reportVEXAS Syndrome:Report of One Case.Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).American journal of hematology
  • Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.Annals of hematology
  • The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high-risk myelodysplastic syndromes.British journal of haematology
  • Myelodysplasia-Related Gene Mutation Burden Is Associated With Complete Remission After Induction Therapy in Acute Myeloid Leukemia, Not Otherwise Specified: Reclassification According to the Updated Classifications.International journal of laboratory hematology
  • Digital surface plasmon resonance imaging for attomolar detection of miR-451a.Biosensors & bioelectronics
  • Case reportDurable Hematologic Response in Therapy-Related Myelodysplastic Syndrome During Nivolumab Treatment for Metastatic Melanoma: A Case Report.Current oncology (Toronto, Ont.)
  • The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.British journal of haematology
  • Qinghuang powder ameliorates cellular senescence and energy metabolism abnormalities in bone marrow mesenchymal stem cells of myelodysplastic syndromes.Journal of ethnopharmacology
  • Somatic RUNX1 exonic deletions in myelodysplastic syndrome: A rare yet high-risk recurrent genetic aberration.HemaSphere